20.70CHF+8.95%Mkt Cap: 815.83M CHFP/E: 345.00Last update: 2026-05-13
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two se…
Industry Peers
Medical Devicesloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)345.00
P/E (Forward)38.54
PEG—
P/B12.19
P/S5.54
EV/EBITDA68.22
EV/Revenue5.38
EPS (TTM)0.06
EPS (Forward)0.53
Cash Flow & Leverage
FCF Yield-0.48%
FCF Margin-2.69%
Operating CF-455.00K CHF
CapEx (TTM)2.44M CHF
Net Debt/EBITDA-1.60
Net Debt-18.38M CHF
Technical
SMA 5023.21 (-10.8%)
SMA 20026.26 (-21.2%)
Beta0.70
S&P 52W Chg24.23%
Avg Vol (30d)201.65K
Avg Vol (10d)251.18K
Technical Indicators
RSI (14)42.8
MACD-1.0931
MACD Signal-1.0052
MACD Hist.-0.0879
BB Upper25.66 CHF
BB Middle21.79 CHF
BB Lower17.91 CHF
BB Width35.60%
ATR (14)1.135 CHF
Vol Ratio (20d)1.66x
52W Range
18.7013% of range34.20
52W High34.20 CHF
52W Low18.70 CHF
Profitability
Gross Margin88.60%
EBITDA Margin7.89%
Profit Margin1.75%
Oper. Margin6.59%
ROE3.02%
ROA1.91%
Revenue Growth66.90%
Earnings Growth—
Balance Sheet
Debt/Equity0.02
Current Ratio1.96
Quick Ratio1.42
Book Value/Sh1.684 CHF
Cash/Share0.5050 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CHF
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateOct 8, 2020
Splits
Last Split1:100
Split DateJun 23, 2016
Ownership
Shares Out.39.41M
Float28.87M
Insiders28.93%
Institutions21.34%
Analyst Consensus
Rating—
Target (Mean)35.40 CHF
Target Range32.80 CHF – 38.00 CHF
# Analysts2
Company
Market Cap815.83M CHF
Enterprise Value785.86M CHF
Revenue (TTM)146.06M CHF
Gross Profit129.40M CHF
Net Income (TTM)2.55M CHF
Revenue/Share3.800 CHF
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees178
Last Price20.70 CHF
CountryCH
SectorHealthcare
IndustryMedical Devices
ISIN—